



## The 65th ASH Annual Meeting Abstracts

## ORAL ABSTRACTS

## 637.MYELODYSPLASTIC SYNDROMES - CLINICAL AND EPIDEMIOLOGICAL

**Validation of the Composite Complete Response (cCR) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) - a Large, Multicenter, Retrospective Analysis from the Validate Database**

Jan Philipp Bewersdorf, MD<sup>1</sup>, Tariq Kewan, MBChir<sup>2</sup>, Ondrej Blaha, PhD<sup>3,4,5</sup>, Maximilian Stahl, MD<sup>6</sup>, Najla H Al Ali, MS<sup>7</sup>, Amy E. DeZern, MDMHS<sup>8</sup>, Mikkael A. Sekeres, MD<sup>9</sup>, Geoffrey L Uy, MD<sup>10</sup>, Hetty E. Carraway, MD MBA<sup>11</sup>, Pinkal Desai, MD MPH<sup>12</sup>, Elizabeth A. Griffiths, MD<sup>13</sup>, Eytan M. Stein, MD<sup>14</sup>, Andrew M. Brunner, MD<sup>15</sup>, Christine M. McMahon<sup>16</sup>, Joshua F. Zeidner, MD<sup>17</sup>, Michael R. Savona, MD<sup>18</sup>, Jessica M. Stempel, MD<sup>19</sup>, Namrata Sonia Chandhok, MD<sup>20</sup>, Constantine Logothetis, MD<sup>21</sup>, Gail J. Roboz, MD<sup>22</sup>, Benjamin Rolles, MD<sup>23</sup>, Eunice S. Wang, MD<sup>13</sup>, Amyah C. Harris<sup>24</sup>, Maria L Amaya, MD PhD<sup>25</sup>, Hayley Hawkins<sup>26</sup>, Justin Grenet, MD MPhil<sup>27</sup>, Rory M. Shallis, MD<sup>28</sup>, Zhuoer Xie, MD MS<sup>29</sup>, Jaroslaw P. Maciejewski, MD, PhD, FACP<sup>30</sup>, David A Sallman, MD<sup>31</sup>, Matteo Giovanni Della Porta, MD<sup>32</sup>, Rami S. Komrokji, MD<sup>7</sup>, Amer M. Zeidan, MBBS, MHS<sup>33</sup>

<sup>1</sup> Memorial Sloan Kettering Cancer Center, New York, NY

<sup>2</sup> Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT

<sup>3</sup> School of Public Health, Yale Center for Analytical Sciences, Yale University, New Haven

<sup>4</sup> Yale Cancer Center, Yale University, New Haven

<sup>5</sup> School of Public Health, Department of Biostatistics, Yale University, New Haven

<sup>6</sup> Dana Farber Institute, Boston, MA

<sup>7</sup> Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

<sup>8</sup> Sidney Kimmel CCC, Johns Hopkins University, Baltimore, MD

<sup>9</sup> Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

<sup>10</sup> Division of Oncology, Washington University School of Medicine, Saint Louis, MO

<sup>11</sup> Department of Hematology and Medical Oncology, Taussig Cancer Institute, Leukemia Program, Cleveland Clinic, Cleveland, OH

<sup>12</sup> Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY

<sup>13</sup> Roswell Park Comprehensive Cancer Center, Buffalo, NY

<sup>14</sup> Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>15</sup> Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

<sup>16</sup> Division of Hematology, University of Colorado School of Medicine, Aurora, CO

<sup>17</sup> University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC

<sup>18</sup> Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN

<sup>19</sup> Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT

<sup>20</sup> Division of Hematology, University of Miami Miller School of Medicine/ Sylvester Comprehensive Cancer Center, Miami, FL

<sup>21</sup> Washington University, Saint Louis, MO

<sup>22</sup> Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY

<sup>23</sup> Brigham and Women's Hospital/Harvard Medical School, Boston, MA

<sup>24</sup> Dana Farber Cancer Institute, Boston

<sup>25</sup> Division of Hematology, University of Colorado, Aurora, CO

<sup>26</sup> Vanderbilt University Medical Center, Nashville

<sup>27</sup> Weill Cornell, New York

<sup>28</sup> Section of Hematology, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT

<sup>29</sup> H. Lee Moffitt Cancer Institute, Tampa, FL

<sup>30</sup> Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

<sup>31</sup> H. Lee Moffitt Cancer Center, Tampa, FL

<sup>32</sup>Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy

<sup>33</sup>Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT

JPB and TK are co-first authors; RK and AMZ are co-senior authors

**Introduction:** Efficacy of therapies used in HR-MDS pts has long been assessed using IWG 2006 MDS criteria, but important limitations in clinical utility and practical application of these criteria have become apparent. The revised IWG response criteria for HR-MDS were proposed in 2023 (Zeidan et al., Blood 2023) were proposed to address these gaps. IWG 2023 re-defined CR by lowering hemoglobin (Hb) threshold from 11 to 10 g/dL and bone marrow [BM] blasts from  $\leq 5\%$  to  $< 5\%$ . Further, CR with partial hematologic recovery (CRh;  $< 5\%$  BM blasts, no Hb threshold, platelets  $\geq 50 \times 10^9/L$ ; neutrophils  $\geq 0.5 \times 10^9/L$ ; peripheral blood [PB] blasts 0%), CR with limited count recovery (CR-L;  $< 5\%$  BM and 0% PB blasts + PB parameters for CR met in 1 [CRuni] or 2 lineages [CRbi]), and CR equivalent (CRequ; defined for pts with baseline BM of  $< 5\%$ .) were all proposed as provisional endpoints. Per IWG 2023 hierarchical response assessment, if a pt met criteria for both CR-L and CRh, they would be recorded as CR-L. We sought to validate the IWG 2023 definitions of cCR (CR+CR-L+CRh+CRequ) in a large, multi-center dataset of HR-MDS pts who received HMAs.

**Methods:** The VALIDATE database includes HR-MDS pts treated with HMA-based therapies in frontline setting from 14 specialized centers. HR-MDS was defined as IPSS  $\geq 1.5$  or IPSS-R  $> 3.5$  (n=213 pts excluded). Pts were excluded (N=90) if age at diagnosis was  $< 18$  years, BM blasts  $\geq 20\%$  or unknown at HMA initiation, or if survival status, follow-up time, HMA type or initiation date were unknown. To preserve validity of response assessments, pts also were excluded (N=290) if no BM evaluation was performed or if first BM assessment was  $> 180$  days after HMA initiation, except in cases of overt disease progression. Best responses were assessed based on IWG 2006 and 2023 criteria. Kaplan-Meier analysis estimated OS from HMA initiation, and the log-rank test was used to compare subgroups. Cox multivariable regression models identified predictors of OS. This study was supported by an independent research grant from AbbVie.

**Results:** Of 1,223 pts in VALIDATE database, 629 were met eligibility. Median age was 68 years, 27.7% and 27.4% were red blood cell and platelet transfusion-dependent, respectively, 38.1% had TP53 mutations, and 45.3% underwent allogeneic transplantation (allo-HCT). Most pts (71.6%) received HMA monotherapy (51.7% azacitidine, 19.9% decitabine), while 28.4% received HMA-based combinations. Median duration of therapy was 4 cycles (Range: 1-94). Median OS of different subgroups pts are shown in **Figure 1**. Median OS for pts with IWG 2023-defined cCR (CR+CR-L+CRh+CRequ; N = 230) was 26.5 months (mo; 95% CI: 20.7 - 32.2 mo) vs 14.3 mo (95% CI: 12.5 - 16.9 mo) for pts who did not achieve cCR (p=0.002). Median OS for pts who achieved IWG 2023-defined CR (N = 90) was 29.8 (95% CI: 23.1 - 41.8) vs. 26.4 mo (95% CI: 22.0 - 41.3) for IWG 2006-defined CR (p=0.71). The 124 pts (19.7%) who achieved CR-L had a median OS of 26.4 mo (95% CI: 17.6 - 36.2 mo); of those 67 pts achieved CRbi and had a median OS of 29.1 mo (95% CI: 20.7 - not reached), while 57 pts achieved CRuni and had a median OS of 18.7 mo (95% CI: 15.5 - 54.4 mo), with no significant difference in OS between CRbi and CRuni (Hazard ratio: 1.24; 95% CI: 0.78-1.98, p=0.71). Given the hierarchical prioritization of CR-L designation over CRh in IWG 2023 if a pt meets both response definitions, only 6 pts achieved CRh which precluded a reliable estimate of their OS. Similarly, CRequ was achieved only in 10 pts limiting a reliable assessment of OS in these pts. In a multivariable Cox model that adjusted for sex, HMA type, age, allo-HCT, complex karyotype, TP53 mutation, and IPSS-M risk group, achieving a cCR per IWG 2023 criteria was statistically significantly associated with improved OS was associated with improved OS compared to those who did not achieve cCR (HR: 1.64; 95% CI: 1.30 - 2.08; p<0.001, **Figure 2**).

**Discussion:** In this real-world analysis of HR-MDS pts treated with HMA-based therapy, cCR according to IWG 2023 were associated improved OS. In particular, CR and CRL (including CRbi and CR uni) were associated with improved OS, supporting their inclusion in the overall response rate in clinical trials. The number of pts who achieved CRh and CRequ was too small to reliably assess their specific association with OS. Additional pts are being added to the database and detailed analyses will be presented in the meeting.

**Disclosures Stahl:** Rigel: Membership on an entity's Board of Directors or advisory committees; Curis Oncology: Other: GME activity ; Dedham group: Consultancy; GSK: Membership on an entity's Board of Directors or advisory committees; Sierra Oncology: Membership on an entity's Board of Directors or advisory committees; Haymarket Media: Other: GME activity ; Kymera: Membership on an entity's Board of Directors or advisory committees; Clinical care options: Other: GME activity ; Boston Consulting: Consultancy; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: GME activity . **DeZern:** Appellis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy; Geron: Membership on an entity's Board of Directors or advisory committees; Sobi: Consultancy; Novartis: Membership on an entity's Board of Directors or advisory committees; Caribou: Membership on an entity's Board of Directors or advisory committees. **Sekeres:** Geron: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kurome: Consultancy, Current holder of stock options in a privately-held company; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees. **Uy:** Jazz: Other: Advisory Board. **Carraway:** Genentech: Consultancy; AbbVie: Other; Daiichi: Consultancy; BMS: Consultancy, Research Funding, Speakers Bureau; Novartis: Consultancy, Other: Travel, Accommodations, Expenses , Speakers Bureau; Stemline Therapeutics: Consultancy, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Other: Travel, Accommodations, Expenses , Speakers Bureau; Celgene: Research Funding; Agios: Consultancy, Speakers Bureau; Takeda: Other; Astex Pharmaceuticals: Other; Syndax: Other: DSMB. **Desai:** Janssen Research & Development: Research Funding; BMS: Consultancy, Other: Advisory role; Abbvie: Consultancy, Other: Advisory role; Servier: Consultancy, Other: Ad-

visory role; *Janssen Pharmaceuticals*: Current Employment. **Griffiths**: *Abbvie*: Consultancy; *Alexion Pharmaceuticals*: Consultancy, Research Funding; *S. Karger Publishing*: Honoraria; *Blueprint Medicines, Inc*: Research Funding; *Bristol Myers Squibb*: Consultancy, Research Funding; *CTI Biopharma*: Consultancy; *Astex Pharmaceuticals*: Research Funding; *MDS International Foundation*: Honoraria; *Picnic Health*: Membership on an entity's Board of Directors or advisory committees; *Genentech, Inc.*: Consultancy, Research Funding; *Artis Ventures*: Membership on an entity's Board of Directors or advisory committees; *Celldex Therapeutics*: Research Funding; *Takeda Oncology*: Consultancy; *AstraZeneca Rare Disease*: Consultancy, Research Funding; *Novartis*: Consultancy, Research Funding; *Apellis Pharmaceuticals*: Consultancy, Research Funding; *NextCure, Inc*: Research Funding; *Partner Therapeutics*: Consultancy; *AAMDSIF*: Honoraria; *Taiho Oncology*: Consultancy; *MediCom Worldwide, Inc.*: Honoraria; *Vera and Joseph Dresner Foundation*: Membership on an entity's Board of Directors or advisory committees; *Medscape*: Honoraria; *American Society of Hematology*: Honoraria; *Physicians Educational Resource*: Honoraria. **Stein**: *Genesis*: Consultancy; *Agios*: Consultancy; *Jazz*: Consultancy; *Menarini*: Consultancy; *Genentech*: Consultancy; *Astellas*: Consultancy; *Ono Pharma*: Consultancy; *Blueprint*: Consultancy; *Abbvie*: Consultancy; *Neoleukin*: Consultancy; *Eisai*: Research Funding; *Bristol Myers Squibb*: Consultancy, Research Funding; *Janssen*: Consultancy; *Novartis*: Consultancy; *Pinot-Bio*: Consultancy; *Gilead*: Consultancy; *Syndax*: Consultancy; *OnCusp*: Consultancy; *CTI Biopharma*: Consultancy; *Foghorn*: Consultancy; *Servier*: Consultancy; *Calithera*: Consultancy; *Daiichi*: Consultancy; *Aptose*: Consultancy; *Syros*: Consultancy. **Brunner**: *Taiho*: Consultancy; *Keros Therapeutics*: Consultancy; *Janssen*: Research Funding; *Agios*: Consultancy, Research Funding; *AstraZeneca*: Research Funding; *GSK*: Research Funding; *Celgene/BMS*: Consultancy, Research Funding; *Novartis*: Consultancy, Research Funding; *Takeda*: Consultancy; *Acceleron*: Consultancy; *Gilead*: Consultancy. **McMahon**: *Syndax Pharmaceuticals*: Research Funding; *Kura Oncology*: Membership on an entity's Board of Directors or advisory committees; *Arcellx*: Membership on an entity's Board of Directors or advisory committees; *Syros Pharmaceuticals*: Research Funding. **Zeidner**: *Takeda*: Research Funding; *Gilead*: Consultancy, Honoraria, Research Funding; *Arog*: Research Funding; *Immunogen*: Honoraria; *Merck*: Research Funding; *Jazz*: Research Funding; *Novartis*: Consultancy; *Astex*: Research Funding; *Daiichi Sankyo*: Honoraria; *Foghorn*: Consultancy; *Sellas*: Consultancy; *Servier*: Consultancy, Honoraria; *Sumitomo Dainippon Pharma*: Research Funding; *Stemline*: Research Funding; *Shattuck Labs*: Honoraria, Research Funding; *AbbVie*: Consultancy, Honoraria, Research Funding. **Savona**: *Karyopharm Therapeutics Inc.*: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; *Ryvu Therapeutics*: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; *Takeda Pharmaceutical Company*: Membership on an entity's Board of Directors or advisory committees, Research Funding; *Boehringer Ingelheim*: Patents & Royalties; *ALX Oncology*: Research Funding; *Astex Pharmaceuticals*: Research Funding; *Taiho*: Membership on an entity's Board of Directors or advisory committees; *TG Therapeutics, Inc.*: Membership on an entity's Board of Directors or advisory committees, Research Funding; *Incyte Corporation*: Research Funding; *Sierra Oncology, Inc.*: Membership on an entity's Board of Directors or advisory committees; *Novartis*: Membership on an entity's Board of Directors or advisory committees; *Geron Corporation*: Membership on an entity's Board of Directors or advisory committees; *Forma Therapeutics Inc.*: Consultancy, Membership on an entity's Board of Directors or advisory committees; *AbbVie Inc.*: Membership on an entity's Board of Directors or advisory committees; *CTI BioPharma Corp.*: Membership on an entity's Board of Directors or advisory committees; *Bristol Myers Squibb*: Membership on an entity's Board of Directors or advisory committees. **Roboz**: *Bluebird bio*: Consultancy; *AZ*: Consultancy; *GSK*: Consultancy; *Astellas*: Consultancy; *BMS*: Consultancy; *Amgen*: Consultancy; *Jasper*: Consultancy; *Jazz*: Consultancy; *MEI*: Consultancy; *Actinium*: Consultancy; *AbbVie*: Consultancy; *Agios*: Consultancy; *Janssen*: Consultancy, Research Funding; *Mesoblast*: Consultancy; *Novartis*: Consultancy; *Pfizer*: Consultancy; *Blueprint*: Consultancy; *Syndax*: Consultancy; *Takeda*: Consultancy. **Wang**: *Kura Oncology*: Speakers Bureau; *BMS*: Consultancy; *Gilead*: Consultancy; *Dava oncology*: Speakers Bureau; *Takeda*: Consultancy; *GlaxoSmithKline*: Consultancy; *Jazz*: Consultancy; *Kite*: Consultancy, Speakers Bureau; *Pfizer*: Consultancy, Speakers Bureau; *PharmaEssentia*: Consultancy; *Astellas*: Consultancy, Speakers Bureau; *Abbvie*: Consultancy; *Novartis*: Consultancy, Speakers Bureau. **Shallis**: *Rigel*: Consultancy; *Curio Science*: Consultancy; *Gilead Sciences*: Consultancy; *Servier*: Consultancy; *Bristol Myers Squibb*: Consultancy. **Xie**: *Moffitt Cancer Center*: Current Employment; *Novartis*: Speakers Bureau. **Maciejewski**: *Regeneron*: Consultancy, Honoraria; *Alexion*: Membership on an entity's Board of Directors or advisory committees; *Novartis*: Honoraria, Speakers Bureau; *Omeros*: Consultancy. **Sallman**: *AbbVie*, *Affimed GmbH*, *Gilead*, *Incyte*, *Intellisphere, LLC*, *Molecular Partners AG*, *PGEN Therapeutics, Inc.*, *Takeda*, *Zentalis*; *Advisory board for AvenCell*, *BlueBird Bio*, *BMS*, *Intellia*, *Jasper Therapeutics*, *Kite*, *Magenta Therapeutics*, *NKARTA*, *Novartis*, *Orbita*: Consultancy; *Aprea*, *Jazz*: Research Funding. **Della Porta**: *Bristol Myers Squibb*: Honoraria, Membership on an entity's Board of Directors or advisory committees. **Komrokji**: *Geron*: Consultancy; *BMS*: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; *AbbVie*, *CTI biopharma*, *Jazz*, *Pharma Essentia*, *Servio*: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; *Rigel*, *Taiho*, *DSI*: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Novartis*: Membership on an entity's Board of Directors or advisory committees. **Zeidan**: *Tyme*: Consultancy, Honoraria; *Gilead*: Consultancy, Honoraria; *Chiesi*: Consultancy, Honoraria; *Syndax*: Consultancy, Honoraria; *BioCryst*: Consultancy, Honoraria; *ALX Oncology*: Consultancy, Honoraria; *Seattle Genetics*: Consultancy, Honoraria; *Incyte*: Consultancy, Honoraria; *Agios*: Consultancy, Honoraria; *Genentech*: Consultancy, Honoraria; *Mendus*: Consultancy, Honoraria; *Otsuka*: Consultancy, Honoraria; *Kura*: Consultancy, Honoraria; *Regeneron*: Consultancy, Honoraria; *Novartis*: Consultancy, Honoraria; *Daiichi Sankyo*: Consultancy, Honoraria; *Taiho*: Consultancy, Honoraria; *Orum*: Consultancy, Honoraria; *Amgen*: Consultancy, Honoraria; *Zentalis*: Consultancy, Honoraria; *Janssen*: Consultancy, Honoraria; *Notable*: Consultancy, Honoraria; *Ionis*: Consultancy, Honoraria; *Servier*: Consultancy, Honoraria; *Shattuck Labs*: Research Funding; *Boehringer-Ingelheim*: Consultancy, Honoraria; *Geron*: Consultancy, Honoraria;

Syros: Consultancy, Honoraria; Schrödinger: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Epizyme: Consultancy, Honoraria; Celgene/BMS: Consultancy, Honoraria; Jazz: Consultancy, Honoraria; Astex: Research Funding; Pfizer: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Foran: Consultancy, Research Funding; Lox Oncology: Consultancy, Honoraria; BeyondSpring: Consultancy, Honoraria; Takeda: Consultancy, Honoraria.

Figure 1: Overall survival by best response




Figure 1: Overall survival by best response was compared using log-rank test. Composite CR was defined as CR + CR-L + CRbi + CRUni. CR – complete remission, CR-L – complete remission with limited hematologic recovery, CRbi – CR with bilineage recovery; CRUni – CR with unilineage recovery; MST – median survival time

Figure 2: Cox multivariable regression model of overall survival

Effect	n = 518 (%)	HR (95% CI)	p-value
Male (vs. Female)	1,403 (1,100,1,845)		0.001
Age (vs. <1 year)		0.998 (0.986,1.009)	0.681
Treatment (vs. AZA)	250 (48.26%)		0.720
- DEC	107 (20.68%)	0.906 (0.686,1.197)	0.489
- Comb	161 (31.68%)	0.922 (0.707,1.202)	0.548
IPSS-2023 (vs. Int. CR)	196 (37.84%)		
- Non-CR	322 (62.16%)	1.640 (1.296,2.075)	< 0.001
Transplant (vs. No)		0.255 (0.193,0.339)	< 0.001
Complex Karyotype (vs. No)		1.400 (1.093,1.951)	0.011
T(PS3 Mutation (vs. No)		1.563 (1.152,2.115)	0.004
IPSS-M Risk (vs. Very High)	217 (41.89%)		0.050
- High	148 (28.57%)	0.872 (0.667,1.139)	0.314
- Moderate High	72 (13.90%)	0.903 (0.416,0.874)	0.006
- Moderate Low	54 (10.42%)	0.590 (0.377,0.925)	0.021
- Low	24 (4.67%)	0.735 (0.408,1.325)	0.306
- Very Low	3 (0.58%)	0.485 (0.067,3.512)	0.474

Figure 2: Forrest plot of variables associated with OS in multivariable regression model among higher risk MDS patients. Hazard ratio for death is shown with 95% CIs. Patients were also excluded if molecular data or information on allo-HCT and follow up were not available. AZA – azacitidine, CI – confidence interval, DEC – decitabine, HR – hazard ratio, IPSS-M – molecular international prognostic scoring system

Figure 1

<https://doi.org/10.1182/blood-2023-180299>

Downloaded from [http://ashpublications.org/blood/article-pdf/142/Supplement\\_1/324/2190751/blood-4928-main.pdf](http://ashpublications.org/blood/article-pdf/142/Supplement_1/324/2190751/blood-4928-main.pdf) by guest on 11 October 2024